Stelara 90 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FKELL
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,250
Award facts
- Contract value 100% obligated
- $16,249.95 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, valued at $16,249.95, awards DMS Pharmaceutical Group Inc. a firm fixed-price contract for the supply of STELARA 90 MG/ML Syringe units to support federal healthcare operations. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025, and represents fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency (DLA). No set-aside designation was applied to this award, allowing the company to compete on an open basis. The product will be delivered to Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its operational headquarters.
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois, continues its longstanding role as a critical supplier in the federal pharmaceutical supply chain through the DLA. The company holds a substantial master contract valued at approximately $500 million through the DLA's SPE2DB program, valid through November 2026, which enables the issuance of delivery orders for a comprehensive range of pharmaceutical products supporting Department of Defense healthcare facilities nationwide. This particular delivery order for Stelara, a biologic immunosuppressant medication, exemplifies the company's core business of distributing specialty pharmaceuticals and biologics to military health facilities. DMS Pharmaceutical Group's consistent contract awards and diverse product portfolio demonstrate its established capability to meet federal pharmaceutical procurement requirements across multiple therapeutic categories.
Quick answers
Who was awarded contract SPE2DB25FKELL?
SPE2DB25FKELL was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 8, 2025.
How much is contract SPE2DB25FKELL worth?
The government has obligated $16,250 on SPE2DB25FKELL.
Is contract SPE2DB25FKELL an order under another contract?
Yes. SPE2DB25FKELL is a delivery order under SPE2DB24D9223, an indefinite delivery contract.
Was contract SPE2DB25FKELL competed?
The extent of competition for SPE2DB25FKELL was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award